Article

What’s New in the Treatment of Osteoporosis?

(AUDIO) That’s the question we put to Dr. Kenneth Saag. In the next few minutes, Dr. Saag, will summarize the latest developments in osteoporosis therapy.

What’s new in the treatment of osteoporosis?

That’s the question we put to Dr. Kenneth Saag, who is Jane Knight Lowe Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham. In the next few minutes, Dr Saag, who is also Professor of Epidemiology, at the UAB School of Public Health, will summarize the latest developments in osteoporosis therapy.

What’s New in the Treatment of Osteoporosis?

 

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Related Content
CAR-T Therapy Gets Fast Tracked for Relapsed/Refractory SLE
December 3rd 2024

CAR-T Therapy Gets Fast Tracked for Relapsed/Refractory SLE

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Laure Gossec, MD, PhD, Professor of Rheumatology, Pitié-Salpêtrière Hospital and Sorbonne University - Pierre et Marie Curie Campus, Paris, France.
Published: November 30th 2024 | Updated: November 30th 2024

Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Zahi Touma, MD, PhD, director, Toronto Lupus Program and Associate Professor of medicine, department of medicine, division of rheumatology, Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto
November 27th 2024

Anifrolumab Delayed Onset of Organ Damage in Patients With SLE

Victoria Johnson
Lihi Eder, MD, associate professor of medicine, Women’s College Hospital and University of Toronto, Canada
November 26th 2024

Guselkumab Similarly Efficacious Among Male, Female Patients With PsA

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.